Loading clinical trials...

The Impact of Implementing a Universal Newborn Screening for Critical Congenital Heart Disease | Clinical Trials | Clareo Health

COMPLETED

The Impact of Implementing a Universal Newborn Screening for Critical Congenital Heart Disease

NCT01749059•Pediatrix

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the impact of implementing a universal pulse oximeter screening as a way to detect critical congenital heart disease in otherwise well-appearing newborns.

Eligibility

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Documentation of informed consent and authorization.
•2. Full term and late preterm newborns (EGA 35-44 weeks)
•3. On room air
•4. Neonates known to have a congenital heart defect at the time of screening, e.g., antenatal diagnosis or diagnosis within the first 24 hours after birth
•5. Parents agree to follow-up contact post discharge

Exclusion Criteria

•1. On supplemental oxygen
•2. Admitted to the Neonatal Intensive Care Unit
•3. Parents do not agree to follow-up
•4. Greater than 30 days of age

Locations (1)

Capital Health Regional Medical Center - Pediatrix Medical Group

Trenton, New Jersey, United States

Key Dates

Start Date

June 1, 2012

Primary Completion Date

October 1, 2016

Completion Date

October 1, 2016

Last Updated

December 19, 2016

Enrollment

6,147

ACTUAL participants

Conditions

Congenital Heart Disease

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

NCT05647213

Univentricular HeartCongenital Heart Disease+2 more

View study

RECRUITINGNA

Aim 3: Pilot Study of a Serious Game to Promote Transition Readiness Skills

NCT07042334

Serious GamesTransition-age Youth+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Impact of Implementing a Universal Newborn Screening for Critical Congenital Heart Disease

Inclusion Criteria

Exclusion Criteria

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Aim 3: Pilot Study of a Serious Game to Promote Transition Readiness Skills

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

Prenatal Maternal Mental Health and Neurodevelopment in Congenital Heart Disease

HIIT in Youth With Congenital Heart Disease (MedBIKE)

PDA for Kidneys Study